Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
orelabrutinib + rituximab + methotrexate
- Development stage
- Phase 3
- Lead developer
- Innocare
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous, Intramuscular, Intrathecal
01
Overview
This is a combination therapy consisting of orelabrutinib (a BTK inhibitor), rituximab (an anti-CD20 monoclonal antibody), and methotrexate (an antimetabolite and antifolate drug). While rituximab + methotrexate combinations have been studied in conditions like rheumatoid arthritis and primary central nervous lymphoma, there is no specific information in the search results about the triple combination with orelabrutinib.
- Other names
- Orelabrutinib, Rituximab, and Methotrexate
02
Targets
Beyond the preview
Go deeper on orelabrutinib + rituximab + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on orelabrutinib + rituximab + methotrexate.